Methylstat, a small molecule inhibitor of Jumonji C domain-containing histone demethylases (JMJD) [49], targeting JMJD1B and JMJD1C proteins, was the drug with the most consistent synergistic interaction with olaparib across the total dosage range (CI = 0.71–0.81; Table 1; Fig. 2A), suggesting it as candidate drug for PARPi sensitization in ovarian cancer. This evidence concerns the gene KDM3B and ovarian carcinoma.